GI Innovation, Inc. (358570.KQ)
KRW 9790.0
(-4.39%)
KRW 9790.0
(-4.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -51.33 Billion KRW | 22.21% |
| 2022 | -67.19 Billion KRW | -123.51% |
| 2021 | -130.03 Billion KRW | -38.35% |
| 2020 | -67.72 Billion KRW | -44.09% |
| 2019 | -49.11 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.8 Billion KRW | 25.99% |
| 2024 Q1 | -12.06 Billion KRW | -143.55% |
| 2023 Q4 | -8.27 Billion KRW | 28.21% |
| 2023 Q3 | -11.53 Billion KRW | 42.72% |
| 2023 FY | - KRW | 22.21% |
| 2023 Q2 | -20.13 Billion KRW | -63.23% |
| 2023 Q1 | -12.33 Billion KRW | 44.63% |
| 2022 Q2 | -16.88 Billion KRW | -42.45% |
| 2022 FY | - KRW | -123.51% |
| 2022 Q4 | -22.27 Billion KRW | -37.69% |
| 2022 Q3 | -16.17 Billion KRW | 4.21% |
| 2022 Q1 | -11.85 Billion KRW | -18.59% |
| 2021 FY | - KRW | -38.35% |
| 2021 Q4 | -9.99 Billion KRW | -146.29% |
| 2021 Q3 | -4.05 Billion KRW | 0.0% |
| 2020 FY | - KRW | -44.09% |
| 2019 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 70.205% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -723.31% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 572.133% |
| Bioneer Corporation | 10.04 Billion KRW | 611.097% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -11623.998% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | -164.704% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | -19.939% |
| Helixmith Co., Ltd | -53 Billion KRW | 3.157% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 173.237% |
| Medy-Tox Inc. | 32.69 Billion KRW | 256.983% |
| Peptron, Inc. | -12.65 Billion KRW | -305.758% |
| Amicogen, Inc. | 13.95 Billion KRW | 467.878% |
| Genexine, Inc. | -40.87 Billion KRW | -25.57% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 723.732% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 28.093% |
| ALTEOGEN Inc. | 440.04 Million KRW | 11764.922% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 149.236% |
| SillaJen, Inc. | -17.35 Billion KRW | -195.811% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 566.312% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -360.981% |
| Genomictree Inc. | -6.33 Billion KRW | -710.674% |
| MedPacto, Inc. | -32.6 Billion KRW | -57.414% |
| D&D Pharmatech | -9.05 Billion KRW | -466.693% |
| EASY BIO,Inc. | 24.32 Billion KRW | 311.035% |